Home › Compare › CDIIQ vs ABBV
CDIIQ yields 2000000.00% · ABBV yields 3.06%● Live data
📍 CDIIQ pulled ahead of the other in Year 1
Combined, CDIIQ + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of CDIIQ + ABBV for your $10,000?
CD International Enterprises, Inc. sources and distributes industrial products in China and the Americas. It operates through two segments, Trading and Consulting. The Trading segment sources and distributes various industrial commodities, such as iron ore, copper concentrate, and other minerals; and cannabidiol-related products. The Consulting segment provides business and management consulting services to public and private American and Chinese companies that operate primarily in China and the Americas. It offers its consulting services in the areas of general business consulting, Chinese regulatory advice, translation services, formation of entities in the People's Republic of China, coordination of professional resources, mergers and acquisitions, strategic alliances and partnerships, advice on effective means of accessing U.S. capital markets, coordination of Sarbanes-Oxley compliance, and corporate asset evaluations. This segment also identifies potential areas of growth; manages and coordinates necessary government approvals and licenses; and provides marketing services, investor relations services, and coordination of the preparation of required SEC filings. The company was formerly known as China Direct Industries, Inc. and changed its name to CD International Enterprises, Inc. in February 2012. CD International Enterprises, Inc. was founded in 2005 and is headquartered in Plantation, Florida.
Full CDIIQ Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.